Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies
Aim: In this retrospective study, the efficacy of adjuvant chemotherapy and its contribution to prognosis were investigated in patients diagnosed with different subgroups of ovarian carcinoma at stages 1–3. Material and Method: Epithelial ovarian carcinoma cases treated at Ankara Oncology Training a...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2019-12-01
|
| Series: | Journal of Oncological Sciences |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336419300573 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849396888192679936 |
|---|---|
| author | Ece Esin İrem Bilgetekin Fatma Buğdaycı Başal Ayşe Ocak Duran Umut Demirci Berna Öksüzoğlu |
| author_facet | Ece Esin İrem Bilgetekin Fatma Buğdaycı Başal Ayşe Ocak Duran Umut Demirci Berna Öksüzoğlu |
| author_sort | Ece Esin |
| collection | DOAJ |
| description | Aim: In this retrospective study, the efficacy of adjuvant chemotherapy and its contribution to prognosis were investigated in patients diagnosed with different subgroups of ovarian carcinoma at stages 1–3. Material and Method: Epithelial ovarian carcinoma cases treated at Ankara Oncology Training and Research Hospital of Health Sciences University between January 2014 and May 2018 were retrospectively analyzed. Results: A total of 145 patients were diagnosed and treated for EOC during the study period. According to histopathological subgroups, serous EOC was the most common (84.8%), followed by endometrioid (6.6%), mucinous (4.8%) and clear cell types (3.8%). Local recurrence and distant recurrences were observed in 39 (43.8%) and 7 (7.9%) cases in the serous EOC group, respectively. The median follow-up was 39 months (10–217 months). Median survival was 91.4 months (58.9–123.9 months) in the whole group and 100.9 months in serous EOC. Median survival in mucinous EOC was 26.2 months, whereas median survival in endometrioid EOC and clear cell EOC were not reached. A statistically significant difference of survival was found between serous and mucinous types of tumors (p: 0.04. Conclusions: According to the results of this study examining the survival outcomes of epithelial ovarian cancer subtypes after chemotherapy, there was a statistically significant difference between the prognosis of different epithelial ovarian cancer cases after taxane and platinum-containing adjuvant chemotherapy. Mucinous type of tumors exhibited less overall survival compared to endometrioid and clear cell types which needs to be confirmed with prospective clinical trials. Keywords: Epithelial ovarian carcinoma, Serous, Mucinous, Adjuvant treatment, FIGO stage |
| format | Article |
| id | doaj-art-f57a971a0c3d49f48d2eae04d42ae5f7 |
| institution | Kabale University |
| issn | 2452-3364 |
| language | English |
| publishDate | 2019-12-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Journal of Oncological Sciences |
| spelling | doaj-art-f57a971a0c3d49f48d2eae04d42ae5f72025-08-20T03:39:13ZengGalenos Publishing HouseJournal of Oncological Sciences2452-33642019-12-0153969910.1016/j.jons.2019.09.002Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologiesEce Esin0İrem Bilgetekin1Fatma Buğdaycı Başal2Ayşe Ocak Duran3Umut Demirci4Berna Öksüzoğlu5Corresponding author. Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Yenimahalle, Ankara, Turkey.; Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Yenimahalle, Ankara, TurkeyDr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Yenimahalle, Ankara, TurkeyDr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Yenimahalle, Ankara, TurkeyDr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Yenimahalle, Ankara, TurkeyDr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Yenimahalle, Ankara, TurkeyDr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Yenimahalle, Ankara, TurkeyAim: In this retrospective study, the efficacy of adjuvant chemotherapy and its contribution to prognosis were investigated in patients diagnosed with different subgroups of ovarian carcinoma at stages 1–3. Material and Method: Epithelial ovarian carcinoma cases treated at Ankara Oncology Training and Research Hospital of Health Sciences University between January 2014 and May 2018 were retrospectively analyzed. Results: A total of 145 patients were diagnosed and treated for EOC during the study period. According to histopathological subgroups, serous EOC was the most common (84.8%), followed by endometrioid (6.6%), mucinous (4.8%) and clear cell types (3.8%). Local recurrence and distant recurrences were observed in 39 (43.8%) and 7 (7.9%) cases in the serous EOC group, respectively. The median follow-up was 39 months (10–217 months). Median survival was 91.4 months (58.9–123.9 months) in the whole group and 100.9 months in serous EOC. Median survival in mucinous EOC was 26.2 months, whereas median survival in endometrioid EOC and clear cell EOC were not reached. A statistically significant difference of survival was found between serous and mucinous types of tumors (p: 0.04. Conclusions: According to the results of this study examining the survival outcomes of epithelial ovarian cancer subtypes after chemotherapy, there was a statistically significant difference between the prognosis of different epithelial ovarian cancer cases after taxane and platinum-containing adjuvant chemotherapy. Mucinous type of tumors exhibited less overall survival compared to endometrioid and clear cell types which needs to be confirmed with prospective clinical trials. Keywords: Epithelial ovarian carcinoma, Serous, Mucinous, Adjuvant treatment, FIGO stagehttp://www.sciencedirect.com/science/article/pii/S2452336419300573 |
| spellingShingle | Ece Esin İrem Bilgetekin Fatma Buğdaycı Başal Ayşe Ocak Duran Umut Demirci Berna Öksüzoğlu Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies Journal of Oncological Sciences |
| title | Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies |
| title_full | Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies |
| title_fullStr | Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies |
| title_full_unstemmed | Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies |
| title_short | Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies |
| title_sort | controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies |
| url | http://www.sciencedirect.com/science/article/pii/S2452336419300573 |
| work_keys_str_mv | AT eceesin controversiesintheefficacyofadjuvantchemotherapyindifferentepithelialovariancarcinomahistologies AT irembilgetekin controversiesintheefficacyofadjuvantchemotherapyindifferentepithelialovariancarcinomahistologies AT fatmabugdaycıbasal controversiesintheefficacyofadjuvantchemotherapyindifferentepithelialovariancarcinomahistologies AT ayseocakduran controversiesintheefficacyofadjuvantchemotherapyindifferentepithelialovariancarcinomahistologies AT umutdemirci controversiesintheefficacyofadjuvantchemotherapyindifferentepithelialovariancarcinomahistologies AT bernaoksuzoglu controversiesintheefficacyofadjuvantchemotherapyindifferentepithelialovariancarcinomahistologies |